A scandal involving the mislabeling of medications, which affected families in Andalucía, Valencia, and Cantabria, has become one of the most talked-about events in recent years in the Spanish pharmaceutical sector. For many parents, the consequences were unexpected: their children suddenly began to develop thick hair growth all over their bodies. This incident not only caused widespread concern but also raised questions about the effectiveness of medication production and distribution controls in the country.
After an extensive investigation, the Málaga prosecutor’s office concluded that there was no criminal wrongdoing on the part of Faram-Química Sur staff. According to El Pais, the error occurred during the packaging stage: several batches of minoxidil, a drug used to stimulate hair growth, were mistakenly labeled as omeprazole, a medicine for treating gastric conditions. These mislabeled batches were distributed to pharmacies in three different regions, resulting in the medication being widely used among children.
Investigation and consequences
In 2019, parents from various regions of the country began contacting doctors after noticing unusual hair growth on the faces, arms, and other parts of their children’s bodies. Medical professionals quickly linked these cases to a syrup intended to relieve reflux symptoms, which in fact contained a completely different substance. The SEFV-H pharmacovigilance system and the Agency for Medicines (Aemps) responded swiftly to the reports, launching a large-scale investigation.
It was soon revealed that the error occurred during production in Malaga. Prosecutors initially considered filing charges for crimes against public health and professional negligence. The accused include the company’s director, the technical manager, and two employees. However, after reviewing medical reports and analyzing the condition of all 21 affected children, it was determined that there were no serious complications and most consequences were limited to cosmetic changes.
Legal outlook
Despite the prosecutor’s position, a trial will still take place, as several families insist on criminal responsibility. The proceedings will involve interrogations of the accused, as well as testimony from parents and medical experts. At this time, a date for the hearings has not been set, but interest in the case remains high, as it could shape future quality control standards in Spain’s pharmaceutical industry.
The prosecutor requested updates from regional health ministries on the children’s conditions two years after the incident. Responses from Valencia, Cantabria, and Andalusia confirmed the absence of serious complications, apart from mild or moderate hypertrichosis in some children. This became a key argument in favor of acquitting the accused.
Context and parallels
The incident of mass hair growth in children has brought back memories of other cases linked to errors in the healthcare system. For example, in Valencia, there was a previous situation where the lack of timely risk communication had tragic consequences for the region — more details are available in the article about the authorities’ response to the threat at the Buseo dam. Such stories highlight the importance of transparency and accountability in the work of public and private institutions responsible for public health.
In recent years, Spain has faced several incidents where mistakes in drug labeling or production led to mass hospital visits. In 2023, there was a case in Catalonia involving incorrect vaccine dosage, and in 2024, a substitution of drugs was discovered in a pharmacy network in Murcia. Each of these cases sparked public outcry and prompted a review of quality control procedures. As a result, there is a growing focus on medication safety and manufacturer accountability, which is gradually changing the approach to pharmaceutical oversight in the country.
